Vaccibody has in a new share issue completed a 35 MNOK (4.3 million €) financing from existing and new investors. The share issue was significantly oversubscribed. The largest new investor is represented by Datum and partners, which will take a seat in the Board of...
Oslo-, Teaneck, New Jersey, June 2, 2014 The Norwegian vaccine company Vaccibody and Phibro Animal Health Corporation (Nasdaq:PAHC), a global animal health and mineral nutrition company, have signed a global exclusive license agreement which grants Phibro and its affiliates the right to develop, market and sell...
A report addressing solutions for strengthening the Norwegian biotechindustry was handed over to the Norwegian government May 20th. Vaccibody was the company being exemplified in the accompanying article in Dagens Næringsliv. Read the article here (Norwegian only)....
The Norwegian Cancer Society (NCS) has recently organized a investment fund for Norwegian companies with a focus on developing novel cancer therapies. With the promising development of VB10.16, Vaccibody’s therapeutic vaccine against HPV induced precancerous lesions, NCS has decided to place their first investment in...
New targeting vaccines for aquaculture based on the Vaccibody concept won 1st prize in Marine Innovation Day (MID) Innovation Award in a conference held in Bergen early in March. The vaccineproject run by researchers at the Norwegian Veterinary Institute and University of Oslo aims to utilize...
The newly published paper by Gunnveig Grodeland et al: DNA Vaccine that Targets Hemagglutinin to MHC Class II Molecules Rapidly Induces Antibody-Mediated Protection against Influenza, describes the vaccibody platform as a robust and effective vaccine for prophylactic use. The paper can be downloaded here...
In a private share issue placement in June Vaccibody raised 733.000 € from existing owners. The funding will be allocated to the company’s development of VB10.16, a therapeutic vaccine against cervical cancer. During the last 6 months Vaccibody has obtained significant progression with conclusive data in...
Please view the new presentation video by CEO Ole Henrik Brekke. Targeting vaccine technology: VB 10.16 a non-invasive treatment of cervical cancer. ...
Vaccibody CSO, Agnete Fredriksen together with Professor Bjarne Bogen and Inger Sandlie published a review in Frontiers in Tumor Immunity. "Targeted DNA vaccines for enhanced induction of Idiotype (Id)-specific B and T cells" is available for download here....
Vaccibody was granted support for the development of a novel therapeutic vaccine against precancerous lesion of the cervix from the Norwegian Research Council’s BIA program. The project period is 4 years and encompasses the collaboration with both Norwegian and UK academic institutions....